UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 195

Sortiert nach

Precision medicine in early breast cancer—beginning of a successful story?

ESMO open, 2023-02, Vol.8 (1), p.100780-100780, Article 100780

2023

Link zum Volltext

Verfügbarkeit prüfen

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

British journal of cancer, 2014-11, Vol.111 (11), p.2051-2057

2014

Link zum Volltext

Verfügbarkeit prüfen

Are BRCA1/2 next generation sequencing results comparable across platforms in Europe? A validation study of BRCA testing in Romanian high-risk breast cancer patients

Breast (Edinburgh), 2017-03, Vol.32, p.S32-S32

2017

Link zum Volltext

Verfügbarkeit prüfen

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Link zum Volltext

Verfügbarkeit prüfen

Hurdles and delays in access to anti-cancer drugs in Europe

Ecancermedicalscience, 2014-11, Vol.8, p.482-482

2014

Link zum Volltext

Verfügbarkeit prüfen

75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy

ESMO open, 2023-05, Vol.8 (1), p.101298, Article 101298

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

The lancet oncology, 2009-02, Vol.10 (2), p.135-146

2009

Link zum Volltext

Verfügbarkeit prüfen

3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Breast (Edinburgh), 2017-02, Vol.31, p.244-259

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-06-11: Is myriad a reliable genetic risk model for prediction BRCA1/2 mutations in Romanian high-risk breast cancer patients?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-06-11

2018

Link zum Volltext

Verfügbarkeit prüfen

Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014

The lancet oncology, 2015-03, Vol.16 (3), p.e137-e147

2015

Link zum Volltext

Verfügbarkeit prüfen

71P Patient-reported understanding of biomarkers associated with metastatic breast cancer (mBC) diagnosis: Results from a global mBC survey in 36 countries

ESMO open, 2024-05, Vol.9, p.103077, Article 103077

2024

Link zum Volltext

Verfügbarkeit prüfen

31 Management of breast cancer in limited-resource countries

European journal of cancer supplements, 2009, Vol.7 (2), p.11-11

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-02

2017

Link zum Volltext

Verfügbarkeit prüfen

P028 - Are BRCA1/2 next generation sequencing results comparable across platforms in Europe? A validation study of BRCA testing in Romanian high-risk breast cancer patients

Breast (Edinburgh), 2017-03, Vol.32, p.S32-S32

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-01

2018

Link zum Volltext

Verfügbarkeit prüfen

Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer

The oncologist (Dayton, Ohio), 2005-10, Vol.10 (9), p.665-685

2005

Link zum Volltext

Verfügbarkeit prüfen

Supportive and palliative care for metastatic breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement

Breast (Edinburgh), 2013-10, Vol.22 (5), p.616-627

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-09-14: Prevalence and type of BRCA mutations in young breast cancer patients undergoing genetic cancer risk assessment in two developing countries: Analysis of two cohorts from Romania and Mexico

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-09-14

2019

Link zum Volltext

Verfügbarkeit prüfen

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TU RAN DOT risk factor analyses

British journal of cancer, 2014, Vol.111 (11), p.2051-2057

2014

Link zum Volltext

Verfügbarkeit prüfen

S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA)

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.S5-S5-6

2011

Link zum Volltext

Verfügbarkeit prüfen

XM02 is superior to placebo and equivalent to Neupogen registered in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

BMC cancer, 2008-01, Vol.8, p.332-332

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety data of an outpatient regimen for pretreated metastatic or relapsed breast cancer (MBC): Vinorelbine, 5-Fluorouracil and Folinic Acid (FuFolNav) — a phase II study

European journal of cancer supplements, 2004-03, Vol.2 (3), p.131-132

2004

Link zum Volltext

Verfügbarkeit prüfen

IN32 - THE ABC OF VACCINATION FOR ADVANCED BREAST CANCER PATIENTS

Breast (Edinburgh), 2021-10, Vol.59, p.S35-S35

Eniu, Alexandru

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 195

Suche als RSS-Feed

Aktive Filter

KollektionOvid

ThemaNeoplasm Staging

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(189)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(107)
Oncology
(57)
Breast Cancer
(36)
Humans
(35)
Female
(28)
Hematology, Oncology And Palliative Medicine
(17)
Cancer
(15)
Breast Neoplasms - Pathology
(14)
Physical Sciences
(14)
Aged
(13)
Middle Aged
(13)
Obstetrics & Gynecology
(13)
Adult
(12)
Patients
(12)
Technology
(11)
Cancer Research
(10)
Chemistry
(10)
Plant Science
(10)
Plant Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Precision medicine in early breast cancer—beginning of a successful story?

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Are BRCA1/2 next generation sequencing results comparable across platforms in Europe? A validation study of BRCA testing in Romanian high-risk breast cancer patients

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Hurdles and delays in access to anti-cancer drugs in Europe

75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Abstract P4-06-11: Is myriad a reliable genetic risk model for prediction BRCA1/2 mutations in Romanian high-risk breast cancer patients?

Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014

71P Patient-reported understanding of biomarkers associated with metastatic breast cancer (mBC) diagnosis: Results from a global mBC survey in 36 countries

31 Management of breast cancer in limited-resource countries

Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

P028 - Are BRCA1/2 next generation sequencing results comparable across platforms in Europe? A validation study of BRCA testing in Romanian high-risk breast cancer patients

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer

Supportive and palliative care for metastatic breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement

Abstract P5-09-14: Prevalence and type of BRCA mutations in young breast cancer patients undergoing genetic cancer risk assessment in two developing countries: Analysis of two cohorts from Romania and Mexico

Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TU RAN DOT risk factor analyses

S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA)

XM02 is superior to placebo and equivalent to Neupogen registered in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Efficacy and safety data of an outpatient regimen for pretreated metastatic or relapsed breast cancer (MBC): Vinorelbine, 5-Fluorouracil and Folinic Acid (FuFolNav) — a phase II study

IN32 - THE ABC OF VACCINATION FOR ADVANCED BREAST CANCER PATIENTS

Aktive Filter

Suchergebnisse filtern